Core Viewpoint - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24%, but has recently experienced a correction of approximately 10% since early October, indicating potential investment opportunities in undervalued stocks [1] Group 1: Market Performance - The MSCI China Healthcare Index has shown a significant year-to-date increase of 59.5% [1] - This index has outperformed the MSCI China Index by 24% [1] - The healthcare sector has seen a recent correction, with a decline of about 10% since early October [1] Group 2: Investment Recommendations - Certain stocks are considered undervalued and attractive, including: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - Junshi Biosciences (02367) - WuXi AppTec Co., Ltd. (02268) - Innovent Biologics, Inc. (01801) - China National Pharmaceutical Group (01177) - All the mentioned stocks have been given a "Buy" rating [1] Group 3: Market Outlook - The capital market is expected to see a recovery in financing activities [1] - There is an anticipated expansion in the trading scale of innovative drugs overseas [1] - Domestic demand for innovative drug research and development is expected to rebound [1] - The U.S. entering a rate-cutting cycle may lead to a recovery in the performance of CXO companies in the second half of the year [1] - The clinical development of authorized innovative drug pipelines overseas is expected to be a significant catalyst for the innovative drug sector [1]

Group 1 - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24% [1] - The healthcare sector has recently experienced a correction, declining approximately 10% since early October, leading to some stocks being viewed as undervalued and attractive [1] - Companies such as 3SBio, Genscript Biotech, Junshi Biosciences, WuXi AppTec, Innovent Biologics, and China National Pharmaceutical Group are favored with a "buy" rating [1] Group 2 - The capital market is expected to see a recovery in financing activities, with an expansion in the overseas trading scale of innovative drugs [1] - There is a rebound in domestic demand for innovative drug research and development, alongside the U.S. entering a rate-cutting cycle [1] - The performance of CXO companies is anticipated to improve in the second half of the year, with the clinical development of authorized innovative drug pipelines overseas being a significant catalyst for the sector [1]

Core Insights - China Duty Free Group (中国中免) made its first appearance on the Hong Kong Stock Connect active trading list in nearly a month, with a trading volume of 1.698 billion HKD and a net sell of 29 million HKD on November 10 [1] - The total trading volume of active stocks on the Hong Kong Stock Connect reached 30.933 billion HKD, accounting for 29.76% of the day's total trading amount, with a net buying amount of 688 million HKD [1] - Alibaba (阿里巴巴-W) led the trading volume with 5.302 billion HKD, followed by SMIC (中芯国际) and Tencent (腾讯控股) with 4.304 billion HKD and 4.019 billion HKD respectively [1] Trading Activity Summary - The active stocks on November 10 included: - Tencent Holdings (00700): 4.019 billion HKD, net sell of 128 million HKD, 20 appearances in the last month, closing price 649.5 HKD, daily increase of 2.44% [1] - SMIC (00981): 4.304 billion HKD, net sell of 217 million HKD, 20 appearances in the last month, closing price 74.7 HKD, daily decrease of 0.99% [1] - Huahong Semiconductor (01347): 1.306 billion HKD, net sell of 198 million HKD, 20 appearances in the last month, closing price 78.1 HKD, daily decrease of 1.70% [1] - Xiaomi Group (01810): 3.256 billion HKD, net buy of 173 million HKD, 20 appearances in the last month, closing price 42.36 HKD, daily increase of 0.28% [1] - Alibaba (09988): 5.302 billion HKD, net sell of 653 million HKD, 20 appearances in the last month, closing price 163.4 HKD, daily increase of 2.06% [1] - Pop Mart (09992): 3.164 billion HKD, net buy of 519 million HKD, 17 appearances in the last month, closing price 221.4 HKD, daily increase of 8.11% [1] - Meituan (03690): 570 million HKD, net sell of 31 million HKD, 13 appearances in the last month, closing price 103.3 HKD, daily increase of 1.27% [1] - CNOOC (00883): 3.742 billion HKD, net buy of 1.313 billion HKD, 13 appearances in the last month, closing price 22.44 HKD, daily increase of 5.95% [1] - China Mobile (00941): 758 million HKD, net sell of 79 million HKD, 7 appearances in the last month, closing price 87.8 HKD, daily increase of 0.75% [1] - Ganfeng Lithium (01772): 1.142 billion HKD, net sell of 74 million HKD, 4 appearances in the last month, closing price 54.0 HKD, daily increase of 2.47% [1] - Sangfor Technologies (01530): 605 million HKD, net sell of 12 million HKD, 3 appearances in the last month, closing price 29.0 HKD, daily increase of 0.62% [1] - Xpeng Motors (09868): 1.067 billion HKD, net buy of 103 million HKD, 3 appearances in the last month, closing price 92.0 HKD, daily increase of 1.21% [1] - China Duty Free Group (01880): 1.698 billion HKD, net sell of 29 million HKD, 1 appearance in the last month, closing price 81.6 HKD, daily increase of 15.34% [1]

Market Overview - On November 10, the Hang Seng Index rose by 1.55%, closing at 26,649.06 points, with a total net inflow of HKD 6.654 billion through the southbound trading channel [1] - The total trading volume for the southbound trading was HKD 103.941 billion, with a net buying amount of HKD 6.654 billion [1] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 63.035 billion, with a net buying of HKD 1.152 billion [1] - The Shenzhen Stock Exchange's southbound trading recorded a transaction amount of HKD 40.906 billion, with a net buying of HKD 5.502 billion [1] Active Stocks - In the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest transaction amount of HKD 30.14 billion, followed by SMIC and Tencent Holdings with transaction amounts of HKD 25.38 billion and HKD 23.94 billion, respectively [1] - In terms of net buying, China National Offshore Oil Corporation (CNOOC) led with a net buying amount of HKD 564 million, with its stock price increasing by 5.95% [1] - Alibaba-W recorded the highest net selling amount of HKD 748 million, while its stock price rose by 2.06% [1] Shenzhen Stock Exchange Active Stocks - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also topped the transaction amount with HKD 22.88 billion, followed by SMIC and CNOOC with transaction amounts of HKD 17.66 billion and HKD 16.28 billion, respectively [2] - CNOOC had the highest net buying amount of HKD 750 million, with its stock price increasing by 5.95% [2] - SMIC recorded the highest net selling amount of HKD 12.6 million, with its stock price declining by 0.99% [2]

Core Insights - On November 10, 2025, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 30.14 billion, 25.38 billion, and 23.94 billion respectively [1][2] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and China National Offshore Oil Corporation (00883) also ranked as the top three, with trading amounts of 22.88 billion, 17.66 billion, and 16.28 billion respectively [1][2] Southbound Stock Connect - Top Active Companies - Alibaba-W (09988) had a trading amount of 30.14 billion with a net buy of -7.48 billion [2] - SMIC (00981) recorded a trading amount of 25.38 billion with a net buy of -91.6453 million [2] - Tencent Holdings (00700) had a trading amount of 23.94 billion with a net buy of -4.19 billion [2] - China National Offshore Oil Corporation (00883) achieved a trading amount of 21.14 billion with a net buy of +5.64 billion [2] - Xiaomi Group-W (01810) had a trading amount of 20.62 billion with a net buy of +2.62 billion [2] - Pop Mart (09992) recorded a trading amount of 18.74 billion with a net buy of +834.075 million [2] - Hua Hong Semiconductor (01347) had a trading amount of 13.06 billion with a net buy of -1.98 billion [2] - Ganfeng Lithium (01772) recorded a trading amount of 11.42 billion with a net buy of -743.079 million [2] - China Duty Free Group (01880) had a trading amount of 10.92 billion with a net buy of -1.47 billion [2] - Xpeng Motors-W (09868) achieved a trading amount of 10.67 billion with a net buy of +1.03 billion [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Alibaba-W (09988) had a trading amount of 22.88 billion with a net buy of +952.690 million [2] - SMIC (00981) recorded a trading amount of 17.66 billion with a net buy of -1.26 billion [2] - China National Offshore Oil Corporation (00883) achieved a trading amount of 16.28 billion with a net buy of +7.50 billion [2] - Tencent Holdings (00700) had a trading amount of 16.25 billion with a net buy of +2.91 billion [2] - Pop Mart (09992) recorded a trading amount of 12.90 billion with a net buy of +4.35 billion [2] - Xiaomi Group-W (01810) had a trading amount of 11.95 billion with a net buy of -883.856 million [2] - China Mobile (00941) achieved a trading amount of 7.58 billion with a net buy of -789.845 million [2] - China Duty Free Group (01880) recorded a trading amount of 6.07 billion with a net buy of +1.18 billion [2] - 3SBio (01530) had a trading amount of 6.05 billion with a net buy of -11.6094 million [2] - Meituan-W (03690) achieved a trading amount of 5.70 billion with a net buy of -306.287 million [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has gained 1.2% with a trading volume of 351 million yuan and a total fund size of 2.079 billion yuan as of November 10 [1] - Key performing stocks within the ETF include InnoCare Pharma-B, Bionet, and Ascletis Pharma, with respective gains of 5.4%, 4.43%, and 4.37% [1] - Conversely, stocks such as Kangzhe Pharmaceutical, MIRXES-B, and Innovent Biologics showed weaker performance, with declines of 1.28%, 0.94%, and 0.65% respectively [1] Group 2 - The innovative drug sector is identified as the largest investment opportunity in the pharmaceutical sector for 2025, with a focus on dual/multi-target drugs, chronic disease medications addressing unmet clinical needs, and ADCs [2] - There is a noted improvement in domestic and international innovative drug financing data, with an upward trend in CXO industry orders, indicating a potential recovery in valuations and performance [2] - The medical device sector is experiencing accelerated approvals for innovative products, such as the approval of the chest and abdominal aortic stent system by Xianjian Technology, which is expected to enhance long-term profit margins [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF and its linked funds passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with the top ten weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Viewpoint - The report from CMB International emphasizes a conservative investment approach, focusing on undervalued stocks in the healthcare sector, particularly in the context of recent market fluctuations and recovery in capital financing [1] Group 1: Market Performance - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24.0% [1] - The healthcare sector has recently experienced a pullback, with the MSCI China Healthcare Index declining by 10% since October [1] Group 2: Investment Opportunities - CMB International identifies several stocks with attractive valuations, including Solid Biosciences (02273), Three-Sixty Biopharma (01530), Giant Biologics (02367), WuXi AppTec (02268), Innovent Biologics (01801), and China Biologic Products (01177) [1] - The report highlights a significant buyback plan from Solid Biosciences, which has repurchased HKD 350 million worth of shares this year, with a total expected return from buybacks and dividends reaching 7% [1] Group 3: Clinical Development and Regulatory Environment - The report stresses the importance of overseas clinical progress for authorized drug pipelines, which is expected to be a catalyst for stock price increases [2] - Three-Sixty Biopharma's collaboration with Pfizer is noted, with two global Phase 3 clinical trials for its drug 707 targeting non-small cell lung cancer and colorectal cancer [2] Group 4: Healthcare Policy and Market Dynamics - The recent healthcare negotiations and the 11th batch of centralized procurement have seen reduced market attention, with 127 drugs participating in negotiations and 55 drugs included in the procurement [3] - The new procurement rules focus on maintaining clinical stability and quality, indicating a shift towards rational price competition in the market [3] - Despite the reduced focus on procurement, the domestic market performance remains a critical variable for overall business performance [3]

s 三生制药 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Views - The report highlights a positive change in the specialty raw materials sector, recommending companies such as Aorite and Prolo Pharmaceuticals [1]. - The report suggests that the Q3 performance of raw material pharmaceutical companies has reached a bottom, indicating potential recovery in profitability as high-cost inventory is consumed [19][20]. Summary by Sections Investment Highlights - The recommended sub-industry rankings are: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12]. - Specific stock recommendations include: - From raw materials: Aorite, Qianhong Pharmaceutical - From Traditional Chinese Medicine: Zorui Pharmaceutical, Fangsheng Pharmaceutical, Dong'e Ejiao - From medical devices: United Imaging Healthcare, Yuyue Medical - From AI pharmaceuticals: Jingtai Holdings - From GLP-1 sector: Lianbang Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, and Innovent Biologics - From PD-1/VEGF dual antibodies: Sanofi Biopharmaceuticals, Kangfang Biologics, and Rongchang Biopharmaceuticals - From innovative drugs: Innovent Biologics, BeiGene, HengRui Medicine, Zai Lab, Baillie Tianheng, Kelun Pharmaceutical, Dize Pharmaceutical, and Haizheng Pharmaceutical [3][15]. Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 18.2%, while the Hang Seng Biotechnology Index has increased by 76.6% [6][11]. - The report notes that the raw material pharmaceutical sector is under pressure due to high base effects and declining prices, with significant revenue impacts [19][20]. R&D Progress and Company Dynamics - Recent approvals include Novartis' radioligand therapy drug, which received dual indications for prostate cancer treatment [2]. - The report provides an overview of ongoing clinical trials and drug approvals, emphasizing the importance of innovation in the pharmaceutical sector [30]. Market Performance - The report indicates that the pharmaceutical sector has experienced adjustments, with notable stock performances including significant gains for companies like Hezhong China (+61%) and Wanze Shares (+30%) [11]. - The report also highlights the performance of various pharmaceutical stocks, noting both gains and losses in the market [16][17]. Raw Material Pricing Trends - The price of 6-APA has dropped significantly, from 370 RMB/kg in 2022 to 180 RMB/kg in October 2025, a decrease of 51% [23]. - The price of Amoxicillin has also decreased from 320 RMB/kg in January 2023 to 190 RMB/kg in October 2025, a decline of 41% [23]. Conclusion - The report suggests that as high-cost inventory is depleted, the gross margins for raw material producers are expected to improve, indicating a potential recovery in profitability for companies like Fuxiang Pharmaceutical and Lukang Pharmaceutical [19][23].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [7] Core Views - The report highlights that the pharmaceutical index decreased by 2.40% during the week of November 3-7, underperforming both the CSI 300 index and the ChiNext index. It emphasizes that some companies in the innovative drug sector have entered the second phase of industry development [12][18] - The report suggests that the innovative drug sector is experiencing a temporary adjustment phase, driven more by trading impacts than fundamental factors. It anticipates a potential market shift that could lead to a new round of growth in the innovative drug sector over the next 5-10 years, with a focus on "disruption" rather than revaluation [13][14] Summary by Sections 1. Industry Performance Review - The pharmaceutical index's performance was characterized by a V-shaped recovery, with the innovative drug sector continuing to adjust while flu-related stocks performed well [2][12] - The report notes that the innovative drug sector is currently not the market's focus, leading to individual stock-driven performance [13] 2. Future Outlook - The report outlines a strategy to continue exploring innovative drugs in preparation for a potential rebound in Q4-Q1, focusing on overseas large pharmaceuticals and small to mid-cap technology revolutions [14] - It expresses optimism for the innovative drug sector leading into 2025, identifying key themes such as overseas large pharmaceuticals, small to mid-cap technology revolutions, and the revaluation of generic drugs [14] 3. Investment Strategy - The report provides a detailed investment strategy for innovative drugs, highlighting key companies such as Innovent Biologics, 3SBio, and others in various therapeutic areas including oncology and chronic diseases [15][16] - It also emphasizes the importance of new technologies like brain-computer interfaces and AI in pharmaceuticals, as well as the internationalization of medical devices [16] 4. Subsector Analysis - The report indicates that the innovative drug index decreased by 3.63% during the same week, underperforming the pharmaceutical index and the CSI 300 index [33] - It highlights the performance of the generic drug sector, which decreased by 4.56%, and notes the challenges faced by traditional Chinese medicine companies due to market pressures [39][48]